logo
  Join        Login             Stock Quote

Mylan (MYL) Launches Generic Version Of Cholesterol Control Lipitor

 May 29, 2012 02:50 PM
 


(By Balaseshan) Mylan Inc. (NASDAQ:MYL), a pharmaceutical company, said its subsidiary launched the generic version of Pfizer Inc.'s (NYSE:PFE) top-selling cholesterol controlling drug Lipitor.

Mylan Laboratories Ltd. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Atorvastatin Calcium Tablets, 10 mg, 20 mg, 40 mg and 80 mg. Mylan is shipping this product immediately.

Atorvastatin Calcium is the generic version of Pfizer's Lipitor Tablets, which are indicated as an adjunct to diet in patients with primary hypercholesterolemia and mixed dyslipidemia to reduce elevated total cholesterol, LDL, triglycerides and to increase HDL cholesterol.

[Related -Mylan, Inc. (MYL) Q3 Earnings Preview: Weak Dollar = Strong Profit?]

Earlier this month, Mylan announced the launch of the generic version of Lipitor in France, Belgium, the UK, the Netherlands and Ireland. Lipitor had U.S. sales of $8.1 billion for the twelve months ending March 31, 2012, according to IMS Health.

On Thursday, Mylan announced the launch of generic version of Roche's osteoporosis treatment Bonviva in the UK and Italy. Osteoporosis is the thinning of bone tissue and loss of bone density over time, common in older women.

On Wednesday, Mylan said its subsidiary launched the generic version of Viramune tablets to treat patients living with HIV/AIDS, after final approval from the U.S. health regulators. This expands further the reach of Mylan's global antiretroviral portfolio.

[Related -Pfizer Inc. (PFE) Q3 Earnings Preview: What To Watch?]

The company announced the launch of generic version of Sanofi-Aventis' (NYSE:SNY) Plavix blood thinning tablets indicated for acute coronary syndrome. Mylan's Pharmaceuticals Inc. has received final clearance from the U.S. health regulators for its ANDA for Clopidogrel Tablets USP, 75 mg and 300 mg.

MYL is trading up 0.79% at $21.80 on Tuesday. The stock has been trading between $15.49 and $25 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageSanDisk Corporation (SNDK) Q1 Earnings Preview: Heads or Tails on Pop or Drop

SanDisk Corporation (NASDAQ:SNDK) will publish its first quarter 2014 financial results press release via read on...

article imageEstee Lauder Companies Inc (EL): Goldman Sachs is Convicted EL Will Make Your Portfolio Prettier

Want to freshen up your portfolio? Goldman Sachs say to add Estee Lauder Companies Inc (NYSE:EL). The read on...

article imageYahoo! Inc. (YHOO) Q1 Earnings Preview: Another Bullish Surprise Coming

Yahoo! Inc. (NASDAQ:YHOO) will discuss the company's financial results for the first quarter ended March read on...

article imageThe Coca-Cola Company (KO) Q1 Earnings Preview: Guidance About to Fizzle?

The Coca-Cola Company (NYSE:KO) plans to release its first quarter earnings results before the market opens read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.